PerkinElmer
check quantity

IFN-β (human) AlphaLISA Detection Kit, 500 Assay Points

The AlphaLISA® Human Interferon β (IFN-β) Detection Kit is designed for detection and quantitation of human IFN-β in serum, buffered solution or cell culture medium in a homogeneous (no-wash steps, no separation steps) assay. The analyte in this kit corresponds to the IFN-β 1a subtype.

This product replaces AL265.

For research use only. Not for use in diagnostic procedures.

Part Number
Unit Size
List Price
Your Price
Quantity
AL3133C
500 assay points
1811.00 USD
 
more
AL3133F
5,000 assay points
12000.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Formats:

  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 μL reaction volume (5 μL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 μL reaction volume (5 μL of sample).

Features:

  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad sample compatibility
  • Small sample volume
  • Results in less than 3 hours
  • Half the time of an ELISA assay

Mature Interferon-beta (IFN-β) contains 166 amino acids with a molecular weight of 22 kDa and is produced in large quantities by fibroblasts in response to pathogens. IFN-β is a cytokine involved in the regulation of unspecific humoral immune responses as well as in immune responses against viral infections. Only small amounts of IFN-&beta are produced under healthy conditions. However, levels can dramatically increase during viral infection, inflammation, and autoimmunity. IFN-β exhibits several biological effects including antiviral and antiproliferative activities. IFN-β has been used, with some success, as a therapeutic agent in the treatment of multiple sclerosis, as well as in chronic active hepatitis B where it appears to be most promising if the disease has not lasted longer than 5 years.

AlphaLISA® technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Specifications

Assay Target IFNβ
Assay Target Class Cytokine
Assay Technology Alpha
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Product Brand Name AlphaLISA
Shipping Condition Blue Ice
Therapeutic Area Oncology, Auto-Immunity
Unit Size 500 assay points
Resources, Events & More
  • All

Application Note

Applicability of AlphaLISA Technology to a Wide Spectrum of Complex Biological Samples

Alpha (Amplified Luminescent Proximity Homogeneous Assay) technology is a bead-based, no-wash alternative to traditional ELISAs. Instead of detection with an HRP substrate, the Alpha assay signal is generated by the excitation of an Eu+-coated bead that has been conjugated to the detection antibody.

Alpha technology offers a simple, straight forward workflow. No wash needed!

  1. Add sample
  2. Add Acceptor bead mix; incubate 1 hr
  3. Add Donor beads; incubate 30 mins
  4. Read on Alpha-enable microplate reader

Download this application note to see how no-wash AlphaLISA® technology provides a more-convenient alternative to ELISA for quantitation of biomarkers in complex sample types, including tissue, serum, and plasma.

PDF 1 MB

Brochure

Alpha Technology Solutions

Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.

PDF 4 MB
Drug Discovery Screening Solutions Brochure

Find out about our range of integrated solutions for drug discovery screening in this e-brochure.

Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automated liquid handling, assays and reagents, imaging and detection systems, and informatics.

Working independently or together, with our solutions you can achieve consistent and accurate results. By accelerating the identification and characterization of effective and safe drug candidates, the PerkinElmer portfolio enables you to optimize efficiency in your lab and deliver more actionable, real-world results.

Download the brochure to learn more about how we can partner with you so that you can discover smarter, more effective, data-driven breakthroughs in the critical screening stages of drug discovery and development.

PDF 4 MB